Abbott Laboratories (ABT), Wednesday announced that its sensor-based glucose technology, the FreeStyle Libre 3 Plus sensor, is now publicly funded in every province across Canada, meaning more people with diabetes can access the glucose sensor.
The product is now covered under federal plans like Non-Insured Health Benefits and by a majority of employer-sponsored workplace benefits programs.
Luz Herrera, general manager of Abbott's diabetes care business in Canada, commented, "The broad coverage is a clear testament to the deep impact and value of our technology."
ABT is currently trading at $127.66, down 0.15 percent on the New York Stock Exchange.
,
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.